Adis Summary of Research: Safety, Effectiveness, and Immunogenicity 6 Months After BNT162B2 mRNA Vaccine in Frail Nursing Home Residents

被引：0
|
作者：
Paik, Julia [1 ]
Al-Salama, Zaina T. [1 ]
机构：
[1] Springer Nat, Private Bag 65901, Auckland 0754, New Zealand
来源：
DRUGS & THERAPY PERSPECTIVES | 2023年 / 39卷 / 09期
关键词：
D O I：
10.1007/s40267-023-01010-3
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Coronavirus disease 2019 (COVID-19) has a high mortality rate among the elderly, particularly among frailer and older individuals living in long-term care facilities (LTCFs). In Spain, a large number of patients in this priority group had received the COVID-19 vaccine, including the mRNA vaccine BNT162B2, by April 2021. This Adis Summary of Research summarizes the effects of the BNT162B2 mRNA vaccine among residents in an LTCF in Spain, based on an observational study. Vaccination in elderly LTCF residents was not linked with an increased safety risk, with no apparent contraindications even in more frail individuals.
引用
收藏
页码：317 / 318
页数：2
相关论文
共 50 条
  • [21] Effectiveness of the BNT162b2 mRNA COVID-19 vaccine in pregnancy
    Dagan, Noa
    Barda, Noam
    Biron-Shental, Tal
    Makov-Assif, Maya
    Key, Calanit
    Kohane, Isaac S.
    Hernan, Miguel A.
    Lipsitch, Marc
    Hernandez-Diaz, Sonia
    Reis, Ben Y.
    Balicer, Ran D.
    NATURE MEDICINE, 2021, 27 (10) : 1693 - +
  • [22] Effectiveness of the BNT162b2 mRNA COVID-19 vaccine in pregnancy
    Noa Dagan
    Noam Barda
    Tal Biron-Shental
    Maya Makov-Assif
    Calanit Key
    Isaac S. Kohane
    Miguel A. Hernán
    Marc Lipsitch
    Sonia Hernandez-Diaz
    Ben Y. Reis
    Ran D. Balicer
    Nature Medicine, 2021, 27 : 1693 - 1695
  • [23] Pronounced antibody elevation after SARS-CoV-2 BNT162b2 mRNA booster vaccination in nursing home residents
    Chong, Yong
    Goto, Takeyuki
    Tani, Naoki
    Yonekawa, Akiko
    Ikematsu, Hideyuki
    Shimono, Nobuyuki
    Tanaka, Yosuke
    Akashi, Koichi
    INFLUENZA AND OTHER RESPIRATORY VIRUSES, 2022, 16 (06) : 1066 - 1071
  • [24] Immunogenicity and Safety of the BNT162b2 mRNA COVID-19 Vaccine in Patients with Melanoma Treated with Immunotherapy
    Diamantopoulos, Panagiotis T.
    Kontandreopoulou, Christina-Nefeli
    Gkoufa, Aikaterini
    Solomou, Elena
    Anastasopoulou, Amalia
    Palli, Eleni
    Kouzis, Panagiotis
    Bouros, Spyros
    Samarkos, Mihalis
    Magiorkinis, Gkikas
    Gogas, Helen
    CANCERS, 2022, 14 (15)
  • [25] Immunogenicity and safety of the mRNA-based BNT162b2 vaccine in systemic autoimmune rheumatic diseases patients
    Basson, Yael Pri-Paz
    Tayar-Shifman, Oshrat E.
    Naser, Rawand
    Matalon, Shelly Tartakover
    Kimhi, Oded
    Gepstein, Raz
    Halperin, Tamar
    Ziv-Baran, Tomer
    Ziv, Amit
    Parikh, Roma
    Kivity, Shaye
    Levy, Yair
    CLINICAL RHEUMATOLOGY, 2022, 41 (12) : 3879 - 3885
  • [26] Immunogenicity and safety of the mRNA-based BNT162b2 vaccine in systemic autoimmune rheumatic diseases patients
    Yael Pri-Paz Basson
    Oshrat E. Tayer-Shifman
    Rawand Naser
    Shelly Tartakover Matalon
    Oded Kimhi
    Raz Gepstein
    Tamar Halperin
    Tomer Ziv-Baran
    Amit Ziv
    Roma Parikh
    Shaye Kivity
    Yair Levy
    Clinical Rheumatology, 2022, 41 : 3879 - 3885
  • [27] Extremely Low Humoral Immune Responses to BNT162b2 Vaccine in Nursing Home Residents Undergoing Hemodialysis
    Kitamura, Mineaki
    Takazono, Takahiro
    Nishino, Tomoya
    Funakoshi, Satoshi
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2021, 32 (10): : 99 - 99
  • [28] Does a lack of vaccine side effects correlate with reduced BNT162b2 mRNA vaccine response among healthcare workers and nursing home residents?
    Oladayo A. Oyebanji
    Brigid Wilson
    Debbie Keresztesy
    Lenore Carias
    Dennis Wilk
    Michael Payne
    Htin Aung
    Kerri St. Denis
    Evan C. Lam
    Christopher F. Rowley
    Sarah D. Berry
    Cheryl M. Cameron
    Mark J. Cameron
    Kenneth E. Schmader
    Alejandro B. Balazs
    Christopher L. King
    David H. Canaday
    Stefan Gravenstein
    Aging Clinical and Experimental Research, 2021, 33 : 3151 - 3160
  • [29] Superior immunogenicity and effectiveness of the third compared to the second BNT162b2 vaccine dose
    Yaniv Lustig
    Tal Gonen
    Lilac Meltzer
    Mayan Gilboa
    Victoria Indenbaum
    Carmit Cohen
    Sharon Amit
    Hanaa Jaber
    Ram Doolman
    Keren Asraf
    Carmit Rubin
    Ronen Fluss
    Ella Mendelson
    Laurence Freedman
    Gili Regev-Yochay
    Yitshak Kreiss
    Nature Immunology, 2022, 23 : 940 - 946
  • [30] Superior immunogenicity and effectiveness of the third compared to the second BNT162b2 vaccine dose
    Lustig, Yaniv
    Gonen, Tal
    Meltzer, Lilac
    Gilboa, Mayan
    Indenbaum, Victoria
    Cohen, Carmit
    Amit, Sharon
    Jaber, Hanaa
    Doolman, Ram
    Asraf, Keren
    Rubin, Carmit
    Fluss, Ronen
    Mendelson, Ella
    Freedman, Laurence
    Regev-Yochay, Gili
    Kreiss, Yitshak
    NATURE IMMUNOLOGY, 2022, 23 (06) : 940 - +
12345